Clinical Trial Update: Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing postoperative immunotherapy to standard chemotherapy for high-risk gastric cancer after surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Immunotherapy (immunotherapy)
• Standard chemotherapy

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Gastric and Esophagogastric Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING